BioSpace News Archive

Leap Therapeutics, Inc. today announced that its Board member, Monica Bertagnolli , MD, has been appointed as the 16th Director of the National Cancer Institute.

Leap Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2022.

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer.

Aptinyx Inc. today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.

GreenLight Biosciences today announced a private placement of approximately $109 million.

Ocugen, Inc announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.

Mind Medicine today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal , effective August 11, 2022 as independent members of its Board of Directors.

Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended June 30, 2022.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2022, and recent corporate highlights.

Terns Pharmaceuticals, Inc. announced that it has agreed to sell, by way of an underwritten public offering, 12,250,000 shares of its common stock at a price of $2.42 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 14,630,000 shares of common stock at a price of $2.4199 per pre-funded warrant, for expected aggregate gross proceeds of approximately $65.0 million, before deducting underwriting discounts and commissions and other offering expenses.